CMV genotyping and drug-resistance assay portfolio from Genient Technologies, including DeepChek UL54, UL56, and UL97 sequencing workflows.
Cytomegalovirus genotyping and drug-resistance workflows can support laboratories studying clinically relevant CMV gene regions. Genient Technologies brings these DeepChek assay options into a practical product portfolio for molecular and virology teams.
The CMV portfolio includes UL54/UL97 and expanded UL54/UL56/UL97 assay options for NGS-based resistance marker workflows.
Select the CMV assay configuration that matches the target genes needed for your drug-resistance workflow.
An NGS-compatible CMV assay focused on UL54 and UL97 gene regions used in drug-resistance workflows.
View Details
An expanded CMV drug-resistance assay adding UL56 coverage alongside UL54 and UL97 targets.
View Details
Our team can help map target region, sequencing platform, sample pathway, and reporting need to a practical genotyping solution.
Talk To Us
Designed for molecular laboratories that need reliable assay options across amplification, sequencing, analysis, and reporting touchpoints.
Assay options focus on UL54, UL97, and optional UL56 coverage for resistance-associated sequence review.
The workflow is positioned for NGS sequencing and downstream analysis in trained molecular laboratories.
DeepChek CMV software/module support helps laboratories interpret and communicate sequencing findings.
Contact Genient Technologies to review target coverage, availability, and workflow fit.
Contact Us